Kalitabs: Uses, Dosage & Side Effects
A potassium chloride extended-release tablet used to treat and prevent hypokalemia (low blood potassium) in adults, commonly prescribed alongside diuretic therapy
Kalitabs is a prescription potassium chloride extended-release tablet containing 750 mg of potassium chloride (equivalent to approximately 10 mmol of potassium) per tablet. It is used to treat and prevent hypokalemia, a condition characterized by abnormally low levels of potassium in the blood. Hypokalemia most commonly occurs as a side effect of diuretic medications used to treat high blood pressure or heart failure. The extended-release formulation delivers potassium gradually through the gastrointestinal tract, reducing the risk of localized high concentrations that can cause nausea, vomiting, and gastrointestinal ulceration. Kalitabs must be swallowed whole and never crushed or chewed. Regular monitoring of serum potassium levels, kidney function, and acid-base balance is essential during treatment.
Quick Facts: Kalitabs
Key Takeaways
- Kalitabs contains 750 mg potassium chloride (approximately 10 mmol K+) in an extended-release formulation designed to minimize gastrointestinal side effects by delivering potassium gradually over several hours.
- It is primarily prescribed to treat and prevent hypokalemia caused by diuretics (such as furosemide, hydrochlorothiazide, or bendroflumethiazide), chronic diarrhea, vomiting, or conditions that increase potassium loss.
- Tablets must be swallowed whole with a full glass of water – never crushed, chewed, or broken – as this can cause dangerous concentrated potassium release and gastrointestinal ulceration.
- Serious drug interactions exist with ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and other medications that raise potassium levels, requiring careful monitoring of serum potassium.
- Regular blood tests to monitor serum potassium, kidney function, and electrolyte balance are essential during treatment, as both hypokalemia and hyperkalemia can cause life-threatening cardiac arrhythmias.
What Is Kalitabs and What Is It Used For?
Kalitabs belongs to the group of potassium supplements, which are medicines used to replace potassium when the body's stores become depleted. Potassium is the most abundant intracellular cation (positively charged ion) in the human body, with approximately 98% of the body's total potassium residing within cells. The remaining 2% is found in the extracellular fluid, including the blood plasma, where its concentration is tightly regulated within the narrow range of 3.5 to 5.0 mmol/L (milliequivalents per liter). Even small deviations outside this range can have profound effects on the function of the heart, muscles, and nervous system.
Potassium plays a critical role in maintaining the electrical potential across cell membranes, which is fundamental to the generation and conduction of nerve impulses, the contraction and relaxation of muscles (including the heart), the regulation of intracellular fluid volume, and the maintenance of normal acid-base balance. The body obtains potassium primarily through dietary sources, particularly fruits (bananas, oranges, avocados), vegetables (potatoes, spinach, tomatoes), legumes, and dairy products. Under normal conditions, the kidneys maintain potassium homeostasis by adjusting the amount of potassium excreted in the urine to match dietary intake.
Hypokalemia, defined as a serum potassium level below 3.5 mmol/L, is one of the most common electrolyte disorders encountered in clinical practice. It is estimated to occur in up to 20% of hospitalized patients and is found in approximately 10–40% of patients taking thiazide or loop diuretics. Mild hypokalemia (3.0–3.5 mmol/L) may be asymptomatic or cause only subtle symptoms such as mild muscle weakness or fatigue. Moderate hypokalemia (2.5–3.0 mmol/L) can lead to more pronounced muscle weakness, leg cramps, constipation, and fatigue. Severe hypokalemia (below 2.5 mmol/L) is a medical emergency that can cause paralysis, rhabdomyolysis (muscle breakdown), respiratory failure, and life-threatening cardiac arrhythmias including ventricular tachycardia and ventricular fibrillation.
The most common cause of hypokalemia is the use of potassium-depleting diuretics, particularly loop diuretics (furosemide, bumetanide) and thiazide diuretics (hydrochlorothiazide, chlorthalidone, bendroflumethiazide). These medications work by increasing urine output, which simultaneously increases renal potassium excretion. Other causes of hypokalemia include chronic or severe diarrhea, prolonged vomiting, excessive sweating, chronic laxative misuse, certain renal tubular disorders, primary hyperaldosteronism (Conn's syndrome), Cushing's syndrome, and inadequate dietary potassium intake, particularly in elderly patients or those with eating disorders.
Kalitabs addresses hypokalemia by providing a direct oral supplement of potassium chloride. The extended-release (also called sustained-release or controlled-release) formulation is specifically engineered to release potassium gradually over several hours as the tablet passes through the gastrointestinal tract. This slow release is a critical safety feature: concentrated potassium solutions and immediate-release potassium formulations are known to cause significant gastrointestinal irritation, including nausea, vomiting, abdominal pain, and in severe cases, ulceration and perforation of the esophagus or small intestine. By distributing the potassium release over a longer portion of the intestinal tract, the extended-release design of Kalitabs significantly reduces these local irritant effects while still providing effective potassium supplementation.
Potassium chloride is the preferred form of potassium supplementation in most clinical situations because hypokalemia caused by diuretics is almost always accompanied by a concurrent loss of chloride (hypochloremic metabolic alkalosis). Replacing both potassium and chloride together corrects both deficiencies simultaneously. Other potassium salts (citrate, bicarbonate, gluconate) are used when hypokalemia occurs in the context of metabolic acidosis or when chloride supplementation is not needed, such as in renal tubular acidosis.
What Should You Know Before Taking Kalitabs?
Contraindications
Kalitabs must not be used in patients with any of the following conditions, as potassium supplementation could cause dangerous or life-threatening hyperkalemia (excessively high blood potassium levels):
- Hyperkalemia: If your serum potassium level is already above the normal range (above 5.0 mmol/L), taking additional potassium is contraindicated. Hyperkalemia can cause fatal cardiac arrhythmias, and potassium supplementation would worsen this condition.
- Severe renal impairment: Patients with severe kidney disease, particularly those with oliguria (reduced urine output, typically less than 400 mL per day) or anuria (no urine output), cannot excrete potassium adequately. Supplemental potassium accumulates rapidly, leading to hyperkalemia.
- Addison's disease (untreated): Adrenal insufficiency causes impaired aldosterone secretion, which leads to potassium retention. Adding exogenous potassium to a patient with uncontrolled Addison's disease can precipitate hyperkalemia.
- Acute dehydration: Severe dehydration impairs renal perfusion and potassium excretion, increasing the risk of potassium accumulation.
- Gastrointestinal obstruction or stricture: The extended-release tablet must pass freely through the gastrointestinal tract. If there is a mechanical obstruction, stricture, or impaired gastrointestinal motility (such as in diabetic gastroparesis or after certain surgeries), the tablet may become lodged and release concentrated potassium locally, causing ulceration or perforation.
- Hypersensitivity: Allergy to potassium chloride or any of the excipients in the formulation.
Warnings and Precautions
Hyperkalemia (serum potassium above 5.5 mmol/L) is a potentially fatal condition that can develop during potassium supplementation, particularly in patients with impaired kidney function or those taking medications that raise potassium levels. Symptoms may include muscle weakness, tingling, irregular heartbeat, and chest pain. Severe hyperkalemia (above 6.5 mmol/L) can cause cardiac arrest. Seek immediate medical attention if you experience these symptoms. Regular blood monitoring is mandatory during treatment.
Before starting and during treatment with Kalitabs, the following precautions should be observed:
- Renal function monitoring: Even mildly reduced kidney function can impair potassium excretion. Your doctor will check your kidney function (creatinine, estimated glomerular filtration rate) before starting Kalitabs and periodically during treatment. Dose adjustments may be necessary as kidney function changes, particularly in elderly patients whose renal function naturally declines with age.
- Regular serum potassium monitoring: Blood tests to measure serum potassium should be performed before initiation of therapy, within one to two weeks of starting treatment or changing the dose, and periodically thereafter. More frequent monitoring is required in patients with impaired renal function, diabetes, or those taking interacting medications.
- Acid-base balance: Potassium homeostasis is closely linked to acid-base status. Metabolic acidosis causes potassium to shift out of cells into the extracellular fluid, which can mask an underlying total body potassium deficit. Conversely, correction of metabolic alkalosis may reveal a hidden hypokalemia. Your doctor will consider acid-base status when interpreting your potassium levels and adjusting your dose.
- Cardiac monitoring: Patients with pre-existing cardiac disease, particularly those with a history of arrhythmias, or those taking digitalis glycosides (digoxin), require careful monitoring. Both hypokalemia and hyperkalemia increase the risk of cardiac arrhythmias, and the therapeutic window for potassium correction may be narrower in these patients.
- Diabetes mellitus: Diabetes, particularly when associated with diabetic nephropathy, impairs renal potassium excretion. Patients with diabetes who are taking Kalitabs require more frequent potassium monitoring.
Pregnancy and Breastfeeding
Potassium is an essential mineral and a normal component of the diet. Potassium chloride supplementation during pregnancy is generally considered safe when prescribed by a healthcare provider to correct a documented deficiency. However, the dose must be carefully controlled and serum potassium levels monitored, as both hypokalemia and hyperkalemia can have adverse effects on the developing fetus and on uterine muscle contractility.
During breastfeeding, potassium is naturally present in breast milk, and supplementation with Kalitabs at prescribed doses is not expected to pose a risk to the nursing infant. Nevertheless, breastfeeding mothers should inform their doctor that they are taking Kalitabs so that appropriate monitoring can be arranged. If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider before taking Kalitabs.
How Does Kalitabs Interact with Other Drugs?
Drug interactions with potassium chloride are primarily pharmacodynamic in nature, meaning they arise from the combined effects of multiple medications on potassium balance rather than from changes in drug metabolism or absorption. The most clinically important interactions involve medications that reduce renal potassium excretion, thereby increasing the risk of hyperkalemia when combined with potassium supplementation.
Major Interactions
| Drug / Drug Class | Mechanism | Clinical Significance | Management |
|---|---|---|---|
| ACE Inhibitors (enalapril, ramipril, lisinopril, perindopril) | Reduce aldosterone secretion, decreasing renal potassium excretion | High risk of hyperkalemia, especially in patients with renal impairment or diabetes | Frequent serum potassium monitoring; reduce Kalitabs dose or discontinue if K+ > 5.0 mmol/L |
| ARBs (losartan, valsartan, candesartan, irbesartan) | Block angiotensin II receptor, reducing aldosterone-mediated potassium excretion | High risk of hyperkalemia, comparable to ACE inhibitors | Frequent serum potassium monitoring; dose adjustment as needed |
| Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Directly reduce renal potassium excretion via aldosterone antagonism or ENaC blockade | Very high risk of hyperkalemia; combination generally avoided | Avoid concurrent use unless under specialist supervision with close monitoring |
| Ciclosporin & Tacrolimus | Reduce renal potassium excretion through tubular effects | High risk of hyperkalemia, particularly in transplant patients | Close potassium monitoring; avoid combination if possible |
| Trimethoprim (alone or in co-trimoxazole) | Blocks ENaC in renal collecting duct, acting like amiloride | Significant risk of hyperkalemia, especially in elderly or renally impaired patients | Monitor potassium within 3–5 days of starting trimethoprim; reduce potassium dose if needed |
Minor Interactions
| Drug / Drug Class | Mechanism | Management |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac) | Reduce renal blood flow and potassium excretion via prostaglandin inhibition | Monitor potassium levels, especially in elderly patients or those with renal impairment |
| Heparin & Low-molecular-weight heparins | Suppress aldosterone synthesis, reducing potassium excretion | Monitor serum potassium during prolonged heparin therapy |
| Beta-blockers (atenolol, metoprolol, propranolol) | Impair cellular potassium uptake by blocking beta-2 receptor-mediated shift | Routine monitoring; risk is low but relevant in combination with other interacting drugs |
| Digoxin | Hypokalemia potentiates digoxin toxicity; correction of hypokalemia is beneficial | Maintaining normal potassium levels is protective; avoid hyperkalemia which also affects cardiac conduction |
Always tell your doctor and pharmacist about all medications you are currently taking, including prescription medicines, over-the-counter products, herbal supplements, and potassium-containing salt substitutes. Many "low-sodium" or "light" salt alternatives contain potassium chloride and can contribute to excessive potassium intake when combined with Kalitabs.
What Is the Correct Dosage of Kalitabs?
The dosage of Kalitabs is highly individualized. Your doctor will determine the appropriate dose based on your serum potassium level, the severity of your deficiency, the underlying cause, your kidney function, and any interacting medications you are taking. The following are general dosing guidelines used in clinical practice:
Adults
| Indication | Serum K+ Level | Typical Daily Dose | Administration |
|---|---|---|---|
| Prevention (with diuretics) | Normal (3.5–5.0 mmol/L) | 2–4 tablets (1,500–3,000 mg / 20–40 mmol K+) | Divided into 2 doses with meals |
| Mild hypokalemia | 3.0–3.5 mmol/L | 4–6 tablets (3,000–4,500 mg / 40–60 mmol K+) | Divided into 2–3 doses with meals |
| Moderate hypokalemia | 2.5–3.0 mmol/L | 6–8 tablets (4,500–6,000 mg / 60–80 mmol K+) | Divided into 3 doses with meals; may require IV supplementation initially |
| Severe hypokalemia | Below 2.5 mmol/L | Usually requires IV potassium | Hospital setting; oral supplementation added once stabilized |
Tablets should always be taken with or immediately after meals and swallowed whole with a full glass of water (at least 200 mL). Taking Kalitabs with food reduces gastric irritation and slows gastric emptying, allowing the extended-release mechanism to function optimally. Never take Kalitabs on an empty stomach, as this increases the risk of gastrointestinal side effects.
Children
Kalitabs extended-release tablets are generally not recommended for children. The tablets cannot be crushed or divided, which makes dose adjustment for smaller body weights impractical. When potassium supplementation is required in pediatric patients, liquid potassium chloride solutions or effervescent potassium preparations are typically used, as these allow precise dose titration based on body weight (typically 1–3 mmol/kg/day). Any potassium supplementation in children should be under specialist pediatric supervision with regular blood monitoring.
Elderly
Elderly patients require particular care when taking Kalitabs. Age-related decline in kidney function reduces the body's ability to excrete potassium, increasing the risk of hyperkalemia. Additionally, elderly patients are more likely to be taking multiple medications that affect potassium balance (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs). Starting doses should generally be at the lower end of the recommended range, with more frequent monitoring of serum potassium and renal function. A typical starting dose for elderly patients is 2 tablets (1,500 mg / 20 mmol K+) daily, with dose adjustments guided by blood test results.
Missed Dose
If you forget to take a dose of Kalitabs, take it as soon as you remember, provided it is not close to the time for your next scheduled dose. If it is nearly time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to compensate, as this increases the risk of hyperkalemia and gastrointestinal side effects. If you are unsure what to do, contact your pharmacist or doctor for advice.
Overdose
A potassium chloride overdose is a medical emergency. Symptoms of severe hyperkalemia include muscle weakness progressing to paralysis, numbness and tingling in extremities, irregular or slow heartbeat, chest pain, and potentially cardiac arrest. If you suspect an overdose, call your local emergency services immediately. Do not attempt to treat severe hyperkalemia at home. Emergency treatment may include intravenous calcium gluconate (to stabilize the heart), insulin with glucose (to shift potassium into cells), sodium bicarbonate, beta-2 agonists (salbutamol), cation exchange resins, and in severe cases, hemodialysis.
Hyperkalemia resulting from overdose typically manifests in a predictable sequence on an electrocardiogram (ECG): peaked T waves appear first (at potassium levels of 5.5–6.5 mmol/L), followed by prolongation of the PR interval and flattening of the P wave (6.5–7.5 mmol/L), then widening of the QRS complex (7.0–8.0 mmol/L), and finally a sine wave pattern that can degenerate into ventricular fibrillation or asystole (above 8.0 mmol/L). The rate of potassium rise matters as much as the absolute level, and patients with chronic hyperkalemia may tolerate higher levels than those with acute rises.
What Are the Side Effects of Kalitabs?
Like all medicines, Kalitabs can cause side effects, although not everybody gets them. The extended-release formulation is specifically designed to minimize gastrointestinal adverse effects compared with immediate-release potassium preparations and potassium solutions. Most side effects are dose-related and can be reduced by taking the tablets with food and adequate fluid, or by adjusting the dose downward. The following side effects have been reported with potassium chloride extended-release preparations:
Common
- Nausea
- Vomiting
- Abdominal pain or discomfort
- Diarrhea
- Flatulence (gas)
- Abdominal distension (bloating)
Uncommon
- Gastrointestinal ulceration (stomach or small intestine ulcers)
- Gastrointestinal bleeding (blood in stool or black stools)
- Esophageal ulceration (particularly if tablets are not swallowed properly)
- Hyperkalemia (elevated blood potassium, especially with impaired kidney function)
- Skin rash
Rare
- Esophageal stricture (narrowing of the esophagus)
- Gastrointestinal perforation
- Small bowel obstruction (tablet lodgement at sites of abnormal narrowing)
- Cardiac arrhythmias secondary to hyperkalemia
Not Known
- Dysphagia (difficulty swallowing) in patients with esophageal compression
- Metabolic alkalosis correction (intended therapeutic effect, not adverse)
Gastrointestinal side effects are the most frequently reported adverse reactions to oral potassium preparations. The extended-release formulation used in Kalitabs has been shown in comparative studies to cause significantly fewer upper gastrointestinal adverse events than wax-matrix potassium tablets or liquid potassium preparations. However, the risk of gastrointestinal ulceration is not eliminated entirely. Post-marketing surveillance data and endoscopic studies have identified that small bowel ulceration can occur with any oral solid-dose potassium formulation, although the overall incidence is low.
The risk of gastrointestinal ulceration is increased in patients who take the tablets lying down (allowing prolonged esophageal contact), those who do not swallow them with adequate fluid, patients with esophageal compression from an enlarged left atrium (as seen in severe mitral valve disease), and patients with delayed gastrointestinal transit. To minimize these risks, always take Kalitabs in an upright position (sitting or standing), with at least a full glass of water, and do not lie down for at least 30 minutes after taking the tablets.
Hyperkalemia is the most serious potential adverse effect of potassium supplementation. While it is uncommon in patients with normal kidney function taking standard doses, the risk increases substantially with renal impairment, concomitant use of potassium-retaining medications, diabetes mellitus, metabolic acidosis, extensive tissue damage (burns, crush injuries), and adrenal insufficiency. Clinical manifestations of hyperkalemia progress from muscular weakness and paresthesias to cardiac conduction abnormalities and potentially fatal arrhythmias.
Contact your doctor or seek medical attention immediately if you experience: severe or persistent abdominal pain, black or bloody stools (suggesting gastrointestinal bleeding), difficulty swallowing, muscle weakness or heaviness in the limbs, tingling or numbness, palpitations or irregular heartbeat, or chest pain. These may be signs of serious side effects requiring urgent medical evaluation.
How Should You Store Kalitabs?
Proper storage of Kalitabs is important to maintain the efficacy and safety of the medication. Potassium chloride extended-release tablets should be stored under the following conditions:
- Temperature: Store at room temperature, not exceeding 25°C (77°F). Do not refrigerate or freeze the tablets. Exposure to excessive heat can affect the integrity of the extended-release matrix, potentially altering the drug release profile.
- Moisture protection: Keep the tablets in the original packaging (blister pack or bottle) to protect them from moisture. Potassium chloride is hygroscopic, meaning it readily absorbs water from the environment. Moisture exposure can cause the tablets to soften, dissolve prematurely, or lose their extended-release properties.
- Light protection: Store away from direct sunlight or strong artificial light. While potassium chloride itself is chemically stable, excipients in the tablet coating or matrix may degrade on prolonged light exposure.
- Child safety: Keep Kalitabs out of the reach and sight of children. Accidental ingestion of multiple potassium tablets by a child can cause severe hyperkalemia and is a medical emergency.
Do not use Kalitabs after the expiry date printed on the packaging (EXP). The expiry date refers to the last day of that month. Do not dispose of medications by flushing them down the toilet or throwing them in household waste. Return unused or expired tablets to your pharmacist for environmentally safe disposal through a take-back program.
If your tablets appear discolored, crumbled, swollen, or otherwise damaged, do not use them. Changes in the physical appearance of extended-release tablets may indicate that the controlled-release mechanism has been compromised, which could lead to an unpredictable and potentially unsafe release of the active ingredient.
What Does Kalitabs Contain?
The active substance in Kalitabs is potassium chloride (KCl), a naturally occurring mineral salt. Each extended-release tablet contains 750 mg of potassium chloride. This is equivalent to approximately 10 mmol (or 10 mEq) of elemental potassium and 10 mmol of chloride. The molecular weight of potassium chloride is 74.55 g/mol, and it appears as a white crystalline powder that is freely soluble in water.
The extended-release formulation is achieved through a matrix system or coating technology that controls the rate of potassium release as the tablet passes through the gastrointestinal tract. Typical inactive ingredients (excipients) in potassium chloride extended-release tablets include:
- Microcrystalline cellulose: A common pharmaceutical excipient used as a filler and to contribute to the matrix structure of the tablet.
- Ethylcellulose: A polymer used in the coating or matrix to control the release rate of potassium chloride. It is insoluble in water and gastrointestinal fluids, creating a barrier through which potassium diffuses slowly.
- Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment during the compression process.
- Colloidal silicon dioxide: A flow agent that improves the uniformity of the tablet mixture during manufacturing.
- Hydroxypropyl methylcellulose (hypromellose): A film-forming agent used in the tablet coating that may also contribute to the controlled-release mechanism.
The specific excipient composition may vary slightly depending on the manufacturer and production batch. For the complete list of excipients in your specific product, refer to the patient information leaflet included in the packaging or consult your pharmacist. If you are known to be allergic to any pharmaceutical excipient, review the full ingredient list before taking Kalitabs.
Frequently Asked Questions About Kalitabs
Kalitabs is a potassium chloride extended-release tablet used to treat and prevent hypokalemia (low potassium levels in the blood). It is most commonly prescribed for patients taking diuretics (water pills) such as furosemide or hydrochlorothiazide, which can deplete the body's potassium stores. Kalitabs is also used in conditions where potassium loss is increased, such as chronic diarrhea, vomiting, or certain kidney disorders. Each tablet contains 750 mg of potassium chloride, providing approximately 10 mmol of potassium.
No, Kalitabs extended-release tablets must never be crushed, chewed, or broken. They must be swallowed whole with a full glass of water. The extended-release formulation is designed to release potassium slowly and gradually in the gastrointestinal tract. Crushing or chewing the tablet destroys this mechanism and can cause a rapid release of concentrated potassium, potentially leading to serious gastrointestinal irritation, ulceration, or even perforation. If you have difficulty swallowing tablets, speak with your doctor about alternative potassium preparations such as liquid solutions or effervescent tablets.
Signs of hyperkalemia (dangerously high potassium levels) include muscle weakness or heaviness in the legs, tingling or numbness in hands and feet, an irregular or slow heartbeat, palpitations, chest pain, nausea, and in severe cases, cardiac arrest. Mild hyperkalemia may be asymptomatic and only detected on blood tests. If you experience any symptoms suggestive of high potassium while taking Kalitabs, seek immediate medical attention. Regular blood tests to monitor serum potassium levels are essential during treatment to detect hyperkalemia before it becomes dangerous.
Kalitabs can interact with several blood pressure medications. ACE inhibitors (such as enalapril, ramipril, and lisinopril) and angiotensin II receptor blockers (ARBs such as losartan and valsartan) reduce potassium excretion by the kidneys, increasing the risk of hyperkalemia when combined with potassium supplements. Potassium-sparing diuretics (spironolactone, eplerenone, amiloride) also raise potassium levels and their combination with Kalitabs is generally avoided unless under specialist supervision. However, potassium-depleting diuretics (furosemide, hydrochlorothiazide) are commonly the reason Kalitabs is prescribed. If you take any blood pressure medications, your doctor will monitor your potassium levels closely and adjust your Kalitabs dose accordingly.
Store Kalitabs at room temperature below 25°C (77°F) in the original packaging to protect from moisture and light. Keep the tablets in a dry place and do not store them in the bathroom or near a sink. Keep Kalitabs out of reach and sight of children. Do not use the medication after the expiry date printed on the packaging. If tablets appear discolored, crumbled, or damaged, do not use them and consult your pharmacist. Return any unused or expired tablets to your pharmacy for safe, environmentally responsible disposal.
If you miss a dose of Kalitabs, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the one you missed, as this increases the risk of hyperkalemia and gastrointestinal side effects. If you frequently forget doses, consider setting a reminder, using a pill organizer, or discussing alternative dosing strategies with your healthcare provider.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Potassium chloride is listed as an essential medicine for electrolyte correction.
- British National Formulary (BNF). Potassium Chloride: Indications, Dose, and Interactions. London: BMJ Group and Pharmaceutical Press; 2025. Accessed February 2026.
- National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summaries: Hypokalaemia. London: NICE; 2024. Evidence-based guidance on diagnosis and management of hypokalemia.
- U.S. Food and Drug Administration (FDA). Potassium Chloride Extended-Release Tablets: Prescribing Information. Silver Spring, MD: FDA; 2024.
- European Medicines Agency (EMA). Summary of Product Characteristics: Potassium Chloride Preparations. Amsterdam: EMA; 2024.
- Palmer BF, Clegg DJ. Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019. Am J Kidney Dis. 2019;74(5):682–695. doi:10.1053/j.ajkd.2019.03.427.
- Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant. 2007;22(12):3471–3477.
- Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol. 2011;7(2):75–84.
- Gennari FJ. Hypokalemia. N Engl J Med. 1998;339(7):451–458. A landmark review of the pathophysiology and clinical management of hypokalemia.
- Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–548.
Editorial Team
This article has been researched, written, and medically reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in internal medicine, nephrology, and clinical pharmacology. Our editorial process follows international standards for medical information:
Researched and written by medical writers with expertise in pharmacology and electrolyte physiology. All clinical claims are supported by referenced peer-reviewed evidence at Evidence Level 1A wherever possible.
Reviewed by the iMedic Medical Review Board, comprising licensed physicians and pharmacists. Content verified against WHO, BNF, NICE, EMA, and FDA guidelines for accuracy and clinical relevance.
All content follows the GRADE evidence framework and is free from commercial influence. iMedic receives no pharmaceutical industry funding, sponsorship, or advertising revenue. See our Editorial Standards.
This article is reviewed at minimum every 6 months and updated when new evidence, guidelines, or safety information becomes available. Last reviewed: May 10, 2026. Report errors via our Contact page.